This project has the following three core technologies:
[1]Antibody-free cell separation and screening technology: Traditional methods have the disadvantages of high cost, time-consuming, lower efficiency and purity. This project uses physical light-induced non-uniform electric field technology to separate and screen rare cells. The innovative technology can be widely used in early detection of cancer cells and prenatal detection of pregnant women.
[2]Antibody-free cell identification and identification technology: the innovative microwave dielectric algorithm with microwave chip and intelligent platform system can quickly identify the type of cell (about 5 minutes), which is helpful for the timeliness of cancer diagnosis.
[3]Next-generation gene sequencing technology: Next Generation Sequencing (NGS) is a high-throughput technology built mainly on the concept of massively parallel sequencing, which achieves simultaneous high-speed sequencing of a large number of nucleic acids.

Our team has developed micro-system chips and prototypes that can be practically used in clinical testing. In response to the pre-clinical coordination of cell experiments to the process of pre-clinical trials, integrated development and production of two new fluidic bio-chip. By improving the morphology and photoelectric characteristics of the film, the roughness is reduced and the life of the photo-generated carrier of the film is reduced, and the characteristic detection and improvement of the stability of the system and chip quality are achieved.

If this technology is used as a health insurance cancer screening project, it will save about 2.1 billion NTD in health care costs annually. In addition, my country＇s one-year prenatal testing market is about 700-900 million NTD, and currently about 32% of women are willing to undergo new forms of fetal genetic testing. Under the policy of opening up the second child in mainland China, there will be 19.8 million pregnant women from 2019, and the market size will exceed 90 billion NTD per year. This technology has a high degree of originality and feasibility and is applicable to the two markets of cancer diagnosis and prenatal testing.